Guideline Summary: Dyslipidemia Management in Polycystic Ovary Syndrome

Prevalence and Need for Screening

Up to 70 % of women with PCOS have dyslipidemia, and this prevalence is independent of obesity status【1】.
All women diagnosed with PCOS should undergo a fasting lipid panel at the time of diagnosis to evaluate cardiovascular risk【1】【3】.
In the United States, approximately 70 % of women with PCOS exhibit dyslipidemia【2】.
Lipid abnormalities persist throughout the reproductive years and continue after menopause【1】.

The characteristic pattern mirrors that of diabetes and metabolic syndrome: elevated triglycerides, reduced HDL‑cholesterol, and normal‑to‑elevated LDL‑cholesterol【4】.
Hypertriglyceridemia is the most common abnormality observed in PCOS【3】.
Elevated LDL‑cholesterol (> 100 mg/dL) is present in 24–40 % of women with PCOS, regardless of body weight【4】.
A higher proportion of small, dense LDL particles—more atherogenic—has been documented【4】.
Reduced apolipoprotein A‑I levels are typical in this population【2】.
Lipoprotein (a) concentrations are increased, especially among non‑obese women with PCOS【4】.
Cholesterol efflux capacity is decreased, indicating impaired reverse‑cholesterol transport【2】.

Dyslipidemia in PCOS results from multiple interacting mechanisms and cannot be explained solely by visceral obesity【1】.
Visceral adiposity and insulin resistance are primary drivers of the lipid disturbances【4】.
Hyperandrogenism independently contributes to adverse lipid profiles【4】.
Genetic and environmental factors also influence lipid metabolism in PCOS【1】.
Compensatory hyperinsulinemia further alters lipid processing【3】.
Anovulatory PCOS phenotypes are associated with more severe dyslipidemia than ovulatory phenotypes【4】.
Lean women with PCOS often exhibit isolated low HDL‑cholesterol, whereas obese counterparts additionally show elevated triglycerides【4】.

Women with PCOS should be screened for additional cardiovascular risk factors, including:
- Family history of premature cardiovascular disease【5】
- Cigarette smoking status【5】
- Impaired glucose tolerance or type 2 diabetes【5】
- Hypertension【5】
- Obstructive sleep apnea【5】
- Obesity, particularly central adiposity【5】
Subclinical atherosclerosis evidence includes:
- Increased carotid intima‑media thickness compared with controls【5】
- Higher prevalence of coronary artery calcification after adjustment for age and BMI【5】
- Elevated left ventricular mass index【5】
- Impaired endothelial function in some studies【5】.
Long‑term data on cardiovascular morbidity and mortality remain inconclusive due to a lack of prospective studies【6】.
Metabolic syndrome occurs 2–5 times more frequently in women with PCOS than in those without the condition【3】.
Among U.S. Caucasian women with PCOS, 34–46 % meet criteria for metabolic syndrome【3】.

Obtain a complete fasting lipid profile at PCOS diagnosis (total cholesterol, LDL‑C, non‑HDL‑C, HDL‑C, triglycerides)【5】.
Repeat lipid testing before initiating and intermittently during hormonal therapy【2】.
Screen for impaired glucose tolerance or type 2 diabetes using an oral glucose tolerance test【5】.
Rescreen glucose metabolism every 3–5 years, or sooner if risk factors worsen【5】.
Measure body mass index and blood pressure at each clinical encounter【5】.

Lifestyle modification is first‑line therapy but generally yields minimal changes in lipid levels, although it improves body composition, hyperandrogenism, and insulin resistance【7】.

Lipid‑lowering agents should not be used to treat hyperandrogenism or infertility【8】.
Metformin shows variable effects on lipid parameters in PCOS【7】.
Estrogen‑containing oral contraceptives raise triglycerides (potentially markedly in genetically susceptible women), raise HDL‑C, and lower LDL‑C by 5–20 %【8】.
Statin therapy may be considered for women who are not planning conception and have elevated cardiovascular risk【8】.
Statins effectively reduce total cholesterol and LDL‑C but are contraindicated during pregnancy【9】.

Do not attribute dyslipidemia solely to obesity; lipid abnormalities occur independent of body weight in PCOS【4】.
Do not overlook lean women with PCOS—they retain significant cardiovascular risk despite normal weight【2】.
Do not delay lipid screening; obtain it at diagnosis because lipid changes begin early in adulthood【1】.
Exercise caution when prescribing estrogen‑containing oral contraceptives to women with pre‑existing hypertriglyceridemia, as they may precipitate severe triglyceride elevation and pancreatitis【7】.
Ensure effective contraception for women of reproductive age who are prescribed statins, given the teratogenic risk【9】.